Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

doi:10.1158/2159-8290.CD-17-0419

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Cancer discovery - 1 Sept 2017

Kondrashova Olga, Nguyen Minh, Shield-Artin Kristy, Tinker Anna V, Teng Nelson N H, Harrell Maria I, Kuiper Michael J, Ho Gwo-Yaw, Barker Holly, Jasin Maria, Prakash Rohit, Kass Elizabeth M, Sullivan Meghan R, Brunette Gregory J, Bernstein Kara A, Coleman Robert L, Floquet Anne, Friedlander Michael, Kichenadasse Ganessan, O'Malley David M, Oza Amit, Sun James, Robillard Liliane, Maloney Lara, Bowtell David, Giordano Heidi, Wakefield Matthew J, Kaufmann Scott H, Simmons Andrew D, Harding Thomas C, Raponi Mitch, McNeish Iain A, Swisher Elizabeth M, Lin Kevin K, Scott Clare L

Abstract excerpt

High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism. We sequenced core HR pathway genes in 12 pairs of pretreatment and postprogression tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CHO Cells

Share to Cricetulus

Share to Drug Resistance, Neoplasm

Share to HEK293 Cells

Share to Indoles

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 28588062
DOI: 10.1158/2159-8290.CD-17-0419
PMCID: PMC5612362

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.PMID 28588062Read ↗

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)Semantic proximity Read ↗

RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.Semantic proximity Read ↗

Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceSemantic proximity Read ↗

Characterization of a <i>RAD51C</i> -Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance DevelopmentSemantic proximity Read ↗

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceSemantic proximity Read ↗

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challengesSemantic proximity Read ↗

Evaluation of Rucaparib and Companion Diagnostics in the PARP Inhibitor Landscape for Recurrent Ovarian Cancer TherapySemantic proximity Read ↗

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.Semantic proximity Read ↗

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaSemantic proximity Read ↗

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancerSemantic proximity Read ↗

Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.Semantic proximity Read ↗

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.